Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies

Documenti analoghi

• Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy
  di: Rafael Madero‐Marroquin, et al.
  Pubblicazione: (2025)
• CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia
  di: Rafael Madero‐Marroquin, et al.
  Pubblicazione: (2024)
• Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia
  di: Tony Marchand, et al.
  Pubblicazione: (2024)
• Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma
  di: Takafumi Shichijo, et al.
  Pubblicazione: (2025)
• CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives
  di: Rui Zhang, et al.
  Pubblicazione: (2025)